These pollutants may be inhaled, absorbed through the skin, or ingested, leading to a buildup of harmful substances in the body
To explore differences in (i) past-year use of GLP-1 or GLP-1/GIP medication to support weight loss and (ii) interest in using a weight-loss medication in the next year between population subgroups, we estimated these proportions stratified by gender, age, ethnicity, occupational social grade, financial situation, health-related economic inactivity, smoking status, alcohol consumption, past-month distress, and history of eating disorders
These attributes position GLP-1-T as a promising candidate for the treatment of metabolic conditions and underscore its potential to address multiple facets of metabolic health
Human clinical trials have focused on post-surgical recovery and GH stimulation, while animal studies cover bone health, body composition, and gastrointestinal function